RhumbLine Advisers’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.89M | Buy |
132,358
+17,596
| +15% | +$366K | ﹤0.01% | 1754 |
|
|
2026
Q1 | $2.68M | Sell |
114,762
-4,037
| -3% | -$87.7K | ﹤0.01% | 1708 |
|
|
2025
Q4 | $2.5M | Sell |
118,799
-12,870
| -10% | -$225K | ﹤0.01% | 1742 |
|
|
2025
Q3 | $2.03M | Buy |
131,669
+2,937
| +2% | +$38.4K | ﹤0.01% | 1911 |
|
|
2025
Q2 | $1.21M | Buy |
128,732
+7,922
| +7% | +$87.2K | ﹤0.01% | 2155 |
|
|
2025
Q1 | $1.48M | Buy |
120,810
+7,361
| +6% | +$104K | ﹤0.01% | 1964 |
|
|
2024
Q4 | $1.5M | Sell |
113,449
-1,010
| -0.9% | -$17.3K | ﹤0.01% | 2032 |
|
|
2024
Q3 | $2.2M | Sell |
114,459
-4,826
| -4% | -$99.7K | ﹤0.01% | 1853 |
|
|
2024
Q2 | $2.45M | Buy |
119,285
+10,291
| +9% | +$215K | ﹤0.01% | 1781 |
|
|
2024
Q1 | $2.59M | Buy |
108,994
+13,677
| +14% | +$305K | ﹤0.01% | 1777 |
|
|
2023
Q4 | $2.06M | Sell |
95,317
-3,652
| -4% | -$56.1K | ﹤0.01% | 1889 |
|
|
2023
Q3 | $1.44M | Buy |
98,969
+671
| +0.7% | +$12.7K | ﹤0.01% | 2019 |
|
|
2023
Q2 | $2.06M | Buy |
98,298
+7,444
| +8% | +$155K | ﹤0.01% | 1892 |
|
|
2023
Q1 | $1.92M | Buy |
90,854
+10,286
| +13% | +$256K | ﹤0.01% | 1826 |
|
|
2022
Q4 | $2.05M | Buy |
80,568
+1,780
| +2% | +$41.5K | ﹤0.01% | 1772 |
|
|
2022
Q3 | $1.89M | Buy |
78,788
+7,522
| +11% | +$169K | ﹤0.01% | 1798 |
|
|
2022
Q2 | $1.37M | Buy |
71,266
+13,027
| +22% | +$217K | ﹤0.01% | 1968 |
|
|
2022
Q1 | $1.01M | Buy |
58,239
+1,516
| +3% | +$25.5K | ﹤0.01% | 2126 |
|
|
2021
Q4 | $1.24M | Sell |
56,723
-776
| -1% | -$14.3K | ﹤0.01% | 2120 |
|
|
2021
Q3 | $1.1M | Buy |
57,499
+2,100
| +4% | +$35K | ﹤0.01% | 2182 |
|
|
2021
Q2 | $951K | Buy |
55,399
+23,631
| +74% | +$433K | ﹤0.01% | 2265 |
|
|
2021
Q1 | $710K | Sell |
31,768
-925
| -3% | -$20.9K | ﹤0.01% | 2339 |
|
|
2020
Q4 | $727K | Buy |
32,693
+1,967
| +6% | +$40.8K | ﹤0.01% | 2278 |
|
|
2020
Q3 | $454K | Sell |
30,726
-3,018
| -9% | -$46K | ﹤0.01% | 2328 |
|
|
2020
Q2 | $500K | Buy |
33,744
+10,270
| +44% | +$156K | ﹤0.01% | 2345 |
|
|
2020
Q1 | $258K | Buy |
23,474
+420
| +2% | +$3.94K | ﹤0.01% | 2468 |
|
|
2019
Q4 | $202K | Buy |
23,054
+203
| +0.9% | +$1.49K | ﹤0.01% | 2745 |
|
|
2019
Q3 | $171K | Sell |
22,851
-140
| -0.6% | -$1.27K | ﹤0.01% | 2784 |
|
|
2019
Q2 | $214K | Buy |
22,991
+3,726
| +19% | +$27.2K | ﹤0.01% | 2769 |
|
|
2019
Q1 | $101K | Sell |
19,265
-145
| -0.7% | -$827 | ﹤0.01% | 2856 |
|
|
2018
Q4 | $86K | Buy |
19,410
+5,350
| +38% | +$29.3K | ﹤0.01% | 2900 |
|
|
2018
Q3 | $114K | Sell |
14,060
-625
| -4% | -$4.46K | ﹤0.01% | 2849 |
|
|
2018
Q2 | $103K | Buy |
+14,685
| New | +$144K | ﹤0.01% | 2869 |
|
Other funds holding SNDX
KCM
DM
EP
HRCM
RhumbLine Advisers's SNDX Position: Q2 2026 in Review
RhumbLine Advisers increased its Syndax Pharmaceuticals (SNDX) stake by 15% in Q2 2026, buying an estimated $366K and bringing the position to 132,358 shares worth $2.89M. The position accounts for ﹤0.01% of the portfolio, ranked #1754.
RhumbLine Advisers first reported a position in SNDX in Q2 2018 and has held it in 33 quarters since. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.
- RhumbLine Advisers held 132,358 shares of Syndax Pharmaceuticals worth $2.89M as of Q2 2026.
- RhumbLine Advisers bought 17,596 Syndax Pharmaceuticals shares in Q2 2026, an estimated $366K.
- Syndax Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1754 holding.
- RhumbLine Advisers first reported a position in Syndax Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.